MASSACHUSETTS GENERAL HOSPITAL
Safety of Anti-CGRP Migraine Therapeutics in Ischemic Stroke
Safety of Anti-CGRP Migraine Therapeutics in Ischemic Stroke is a funding opportunity from MASSACHUSETTS GENERAL HOSPITAL, up to 532299, closing May 31, 2028.
May 31, 2028
(670d left)Overview
Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists (“gepants”) and anti-CGRP or anti- CGRP-receptor monoclonal antibodies (“nezumabs”) are novel treatments for migraine. However, endogenous CGRP is among the most potent vasodilator molecules, and CGRP-mediated vasodilation is a critical…